Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Rectal Neoplasms 1Neoplasms 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 5Nivolumab 5Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1sintilimab 1regorafenib 1fludarabine phosphate 1fludarabine 1danvatirsen 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Interleukin-2 1Immunoglobulin G 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Diffusion Tensor Imaging × Gastrointestinal × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡